Link Pharma Chem Ratios

Link Pharma Chem Ltd Ratios

The Link Pharma Chem Ltd Ratios page provides a complete fundamental analysis of Link Pharma Chem Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Link Pharma Chem Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Link Pharma Chem Ltd (NSE: , BSE: 524748) is currently trading at ₹24.86, with a market capitalization of ₹110.39M. As a major player in the Process industries sector and Chemicals: specialty industry, Link Pharma Chem Ltd remains a key stock for fundamental analysis using Link Pharma Chem Ltd Ratios.

Link Pharma Chem Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Link Pharma Chem Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Link Pharma Chem Ltd Ratios.

Historically, the Link Pharma Chem Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 24.85
• 2021: 9.50
• 2020: 9.68

The decline in Link Pharma Chem Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Link Pharma Chem Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.19.

Historical P/B trend:

• 2024: 1.19
• 2023: 1.36
• 2022: 1.08
• 2021: 1.23

Link Pharma Chem Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Link Pharma Chem Ltd P/S ratio currently stands at 0.59, an important part of Link Pharma Chem Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.59
• 2023: 0.63
• 2022: 0.42
• 2021: 0.33

A stable or declining Link Pharma Chem Ltd P/S ratio indicates cautious market sentiment.

Link Pharma Chem Ltd Price to Cash Flow Ratio (P/CF)

The Link Pharma Chem Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 7.61.

Historical Link Pharma Chem Ltd Price to Cash Flow Ratio:

• 2024: 7.61
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 2.38

The rising Link Pharma Chem Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Link Pharma Chem Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Link Pharma Chem Ltd EV currently stands at ₹207.31M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 207.31M
• 2023: 278.23M
• 2022: 248.16M
• 2021: 233.78M

Link Pharma Chem Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Link Pharma Chem Ltd EV/EBITDA ratio is currently 159.47, a key metric in Link Pharma Chem Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 159.47
• 2023: 0
• 2022: 9.13
• 2021: 6.67

Higher Link Pharma Chem Ltd EV/EBITDA suggests premium valuation.

Link Pharma Chem Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Link Pharma Chem Ltd D/E ratio is currently 0.46, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.46
• 2023: 0.67
• 2022: 0.58
• 2021: 0.44

Link Pharma Chem Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Link Pharma Chem Ltd ROE currently stands at -7.79%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -7.79
• 2023: -9.48
• 2022: 4.43
• 2021: 13.92

Declining ROE indicates pressure on profitability.

Link Pharma Chem Ltd Ratios Analysis Summary

The Link Pharma Chem Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Link Pharma Chem Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Link Pharma Chem Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.